I-MAK’s team has spent the last decade increasing transparency on patents, innovation, and access.

Secondary Patenting of Branded Pharmaceuticals: A Case Study of How Patents on Two HIV Drugs Could Be Extended for Decades

T Amin and AS Kesselheim Health Aff 2012 Oct;31(10):2286-94. doi: 10.1377/hlthaff.2012.0107. Abstract Pharmaceutical manufacturers rely on patents to protect their intellectual property and often seek to extend market exclusivity for their products to maximize their return on investment. One method is by obtaining patents on features other than the original active drug ingredient, including secondary…

Journal Articles 14 Oct 2012

Briefing Memo: Risks Of The Trans-Pacific Free Trade Agreement For Access To Medicines – Analysis Of The Leaked U.S. Paper Eliminating Patent Pre-Grant Opposition

A leaked U.S. paper recently circulated to countries negotiating the TransPacific Partnership Agreement (TPPA) outlines the U.S. argument for eliminating “pre-grant opposition,” an important tool for preventing patent applicants from gaining patent monopolies based on weak or erroneous information, for improving the quality and efficiency of patent office examinations, and for safeguarding access to medicines.

Briefs & Fact Sheets 18 Jul 2011

Join us to stay updated
and help make lifesaving medicines accessible to all